12-Lipoxygenase Inhibitor Improves Functions of Cytokine-Treated Human Islets and Type 2 Diabetic Islets

Area of Science:

• Endocrinology
• Metabolic Diseases
• Molecular Biology

Background:

• The 12-lipoxygenase (12-LO) pathway is implicated in islet inflammation in type 1 and type 2 diabetes (T2D).
• Inflammation can impair pancreatic islet function, crucial for glucose regulation.

Purpose of the Study:

• To evaluate the efficacy of ML355, a selective 12-LO inhibitor, in preserving human islet function.
• To determine if ML355 can counteract inflammation-induced dysfunction and improve function in T2D islets.

Main Methods:

• Human islets were exposed to inflammatory cytokines (TNF-α, IL-1β, IFN-γ) to model inflammation.
• Cytokine-treated islets and islets from T2D donors were incubated with or without ML355.
• Insulin secretion and oxygen consumption rate (OCR) were measured under glucose stimulation.

Main Results:

• ML355 prevented the decrease in insulin secretion and OCR in cytokine-treated human islets.
• ML355 improved both insulin secretion and OCR in human islets from T2D donors.
• The 12-LO inhibitor demonstrated protective effects on islet function in vitro.

Conclusions:

• ML355 effectively improved human islet function under inflammatory conditions and in T2D islets.
• Blocking the 12-LO pathway is a potential therapeutic strategy for both type 1 and type 2 diabetes.
• Further in vivo studies of ML355 are warranted to explore its therapeutic potential.